Results 31 to 40 of about 94,347 (282)
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Journal of Experimental & Clinical Cancer Research, 2021 The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) are two most representative immune checkpoint pathways, which negatively regulate T cell immune function during different ...
Hao Zhang +8 more
doaj +1 more source
Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8+ T cell [PDF]
, 2012 During the primary response, the commitment of the CD8(+) T cell to Blimp-1 expression and the terminal differentiation that Blimp-1 induces must be timed so as not to impair the process of clonal expansion. We determined whether the Hippo pathway, which
A. Hoffmann +42 more
core +1 more source
Frontiers in Immunology, 2022 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) haploinsufficiency is a T-cell hyperactivation disorder that can manifest with both immunodeficiency and immune dysregulation. Approximately one-third of patients may present mild symptoms and remain stable under
Adriana Margarit-Soler +30 more
doaj +1 more source
CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]
, 2018 The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro +15 more
core +3 more sources
CTLA-4 is a second receptor for the B cell activation antigen B7. [PDF]
The Journal of experimental medicine, 1991 Functional interactions between T and B lymphocytes are necessary for optimal activation of an immune response. Recently, the T lymphocyte receptor CD28 was shown to bind the B7 counter-receptor on activated B lymphocytes, and subsequently to costimulate interleukin 2 production and T cell proliferation.
P S, Linsley +5 more
openaire +2 more sources
Journal for ImmunoTherapy of Cancer, 2021 Background Sipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC).
Padmanee Sharma +12 more
doaj +1 more source
MALT1 proteolytic activity suppresses autoimmunity in a T cell intrinsic manner [PDF]
, 2019 MALT1 is a central signaling component in innate and adaptive immunity by regulating NF-kappa B and other key signaling pathways in different cell types. Activities of MALT1 are mediated by its scaffold and protease functions.
Baens, Mathijs +7 more
core +2 more sources
64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. [PDF]
PLoS ONE, 2014 Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) targeted therapy by anti-CTLA-4 monoclonal antibody (mAb) is highly effective in cancer patients.
Kei Higashikawa +6 more
doaj +1 more source
Cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibits CD28-induced IκBα degradation and RelA activation [PDF]
European Journal of Immunology, 1999 Purified CD4+ cells from the spleens of C57BL/6 mice were stimulated with anti-CD3, anti-CD28 and anti-cytotoxic T lymphocyte antigen (CTLA)-4 monoclonal antibodies. The results show that CTLA-4 stimulation inhibits IL-2 production induced by CD3-CD28 co-stimulation.
C, Pioli, L, Gatta, D, Frasca, G, Doria
openaire +2 more sources
PLoS ONE, 2015 The immune suppressive protein CTLA-4 is constitutively expressed by Tregs and induced in effector T cells upon activation. Its crucial role in adaptive immunity is apparent from the fatal autoimmune pathology seen in CTLA-4 knockout mice.
Louisa E Jeffery +8 more
doaj +1 more source